Jeff Schmitt, PhD
Educator, advocate, technology and research executive with 40 years experience in life sciences research and leadership; serial entrepreneur; proven ability to build organizations, research programs and foster innovation. Excellent track record in building institutional capacity and in translating science into commercial value. Extensive translational and pharmaceutical research experience. Expert at assessing commercial feasibility and pipeline acceleration. Previous background in high performance computing and IT administration. Excellent business development and leadership skills. Strategic thinker with a global perspective.
100+ publications, patents and PCTs / key player in raising $100M+ in venture funding / strong visionary leader
PROFESSIONAL EXPERIENCE
• Chief Scientific Officer, Sanesco Inc, 2016-2021
Created
• Founding Director, Innovation and Entrepreneurship Initiative (Wake Forest Innovations / Innovation Quarter), Wake Forest School of Medicine, 2010-2015
Created and implemented novel programs to generate new revenue sources. Built a successful team of experts to assist faculty in translation of research outcomes ot value-creating intellectual capital and partnerships. Developed sutting-edge grant programs and education frameworks to help academic researchers ensure success in challenging economic times. Spearheaded the development of Chemical Biology research and infrastructure as well as an academic drug discovery pipeline at the medical center. Developed numerous wealth creation models based on high-tech industry best practices.
• Professor of Biochemistry with cross appointments in Physiology-Pharmacology, Center for Complementary and Integrative Medicne and the Translational Sciences Institute, 2010-2016
Since beginning his employment in 1981, Dr. Schmitt has been conducting research at Wake Forest School of Medicine in various capacities. Member of team that elucidated metabolic and biosynthetic pathways of platelet activating factor. Co-investigator on project that elucidated a mechanism thru which omega-3 fatty acids lower stress. Member of team that elucidated key mechanisms of white blood cell activation by lipid mediators. Coinvestigator on prestigious Delartment of Defense Lab to Clinic grant for the development of prostate cancer therapeutics. Expertise in Systems Biology and Chemical Biology.
• Research Director and Co-Founder, The Bent Creek Institute (University of N. Carolina), 2007-2010
Scientience and strategy leader in establishing biotechnology in Western North Carolina. Guided team in providing critical sustainable economic development infrastructure, including North America’s first plant seed and tissue bank dedicated to plants and fungi of medicinal and natural products industry interest (http://www.youtube.com/user/BCI4You). Worked extensively with North Carolina legislature to promote and fund the Insitute.
• Chief Scientific Officer and Co-Founder, Genesis Molecular Discovery, Inc. 2006-2007
With co-founders Peter Crooks and Stuart Kauffman, developed technology to synthesize large numbers of novel molecules and screen them for biological activity. Co-developed business and R&D plans and participated in fundraising and infrastructure development.
• Director of Molecular Design, Principal Scientist and founding company member, Targacept Inc. 1994-2007
Participated in nearly all aspects of the company’s development including: business and research planning, building an extensive computational drug design platform called PentadTM, medicinal chemistry, pharmacology, fundraising, building of a strong patent portfolio (inventor on 26 Targacept patents) and preclinical research. Three drugs designed by Schmitt and co-workers have reached clinical trials. PI on a prestigious $2M Advanced Technology program grant from the National Institute of Standards and technology used to drive the development of Targacept’s drug discovery platform. Spearheaded development of the first supercomputing grid on the East coast based on community/municipal resources. Principal investigator in first consortium to develop quantum molecular dynamics for drug discovery.
Additional Experience and Skills
• Nonprofit Board Director
Extensive experience in the not-for-profit sector; served on the Boards of numerous organizations over the past 20 years; on three of the boards he was elected chairman (heartofthehealer.org; themap.org; albanelved.com).
• Exellent Communitor / Experienced Presenter / Advocate / Educator
TEDx presenter. Over 100 invited presentations and expert panels. Lecture experience in a broad variety of life-science and transdisciplinary topics. Undergraduate/graduate research advisor to 12 students.
• Editor
7 Editorial positions on international science journals; ad hoc reviewer on 8 international science journals.
EDUCATION
WAKE FOREST UNIVERSITY
BS Honors, 1988
UNIVERISTY OF BATH, UK / OXFORD UNIVERSITY, UK
PhD Honors, 1998
ACADEMIC CV
KEY ACCOMPLISHMENTS:
▫ 40 year career in life-science research and leadership
▫ Member of team that elucidated metabolic and biosynthetic pathways of platelet activating factor
▫ Co-investigator on project that elucidated a mechanism thru which omega-3 fatty acids lower stress
▫ Member of team that elucidated key mechanisms of white blood cell activation by lipid mediators
▫ Founding team member of Targacept, Inc
▫ Chief Architect of Targacept’s platform drug design technology ‘PENTAD’
▫ Established North Carolina’s first community-based grid computing initiative for scientific research (the first scientific computing grid in the Southeast)
▫ Participated in the design and development of 7 drugs evaluated in human clinical trials
▫ Principal investigator in first project to develop quantum molecular dynamics for drug discovery
▫ 99 published/issued papers, abstracts, patents and PCTs
▫ Founding member of The Bent Creek Institute of the University of North Carolina
▫ Founding member of North America’s first medicinal plant seed and tissue bank
EDUCATION AND TRAINING:
▫ St. Andrews College, Laurinburg, North Carolina, USA 1980-1981
▫ B.S. Cum Laude (Chemistry), Wake Forest University, Winston-Salem, North Carolina, USA 1988
▫ Ph.D. Honors University of Bath, visiting scientist Oxford University, England (Biochemistry & Biophysics) 1995-1998
SOCIETY MEMBERSHIPS:
▫ New York Academy of Sciences, 1998-2004
▫ Union of Concerned Scientists, 1998-2005
▫ American Chemical Society, 2000-2013
▫ American Society of Pharmaceutical Scientists 2004-2010
ACADEMIC APPOINTMENTS AND OTHER PRIMARY POSITIONS (see above or most recent appointments):
▫ Laboratory Technician, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 1980-1991
▫ Research Assistant, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 1991-1995
▫ Research Associate, Division of Pharmacology, RJR-Nabisco, Bowman-Gray Technical Center, Winston-Salem, North Carolina, 1992-1995
▫ Molecular Design and IT Group Leader, Targacept, Bowman-Gray Technical Center, Winston-Salem, North Carolina, 1995-2001
▫ Adjunct Lecturer, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 1998-2003
▫ Director Molecular Design Group, Targacept Inc., Winston-Salem, North Carolina, 2001-2005
▫ Member, Winston-Salem Center for Nonviolent Communication Taskforce, 2001-2002
▫ Co-Chair & Founder, Winston-Salem High Performance Computing Initiative, 2001-2003
▫ Member, Executive Committee, Winston-Salem Chamber of Commerce Technology Council, 2002
▫ Member, Board of Directors, Alban Elved Dance Company, 2002-2004
▫ Adjunct Associate Professor, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 2002-2008
▫ Member, Science Advisory Board, University of North Carolina at Greensboro, 2003-2005
▫ Chair, Board of Directors, Alban Elved Dance Company, 2003-2004
▫ Computational Drug Discovery Focus Group Leader, American Association of Pharmaceutical Scientists, 2004-2007
▫ Steering and Leadership Committee member American Association of Pharmaceutical Scientists, 2004-2007
▫ Member, Advisory Board, Degree Program in Digital Design, North Carolina School of the Arts, 2004
▫ Principal Scientific Advisor, Targacept, Winston-Salem, North Carolina, 2005-2007
▫ Chief Scientific Officer, Genesis Molecular Discovery, 2004-2005
▫ Research Professor, University of North Carolina at Asheville, Asheville, North Carolina, 2006-present
▫ Member, Advisory Board, The Advisory Committee for Biotechnology in Western North Carolina, 2007-present
▫ Founding Director, Institute for Natural Biotechnology and Integrative Medicine, University of North Carolina Asheville, North Carolina, 2007-present
▫ Vice-Chair, Board of Directors, the Media Arts Project, Asheville, North Carolina, 2007-2008
▫ Adjunct Professor, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 2008-present
▫ Adjunct Professor, Translational Sciences Institute, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 2008-2017
▫ Chair, Board of Directors, the Media Arts Project, Asheville, North Carolina, 2008-2010
▫ Member, Advisory Board, Blue Ridge Sustainability Institute, Asheville, North Carolina, 2008-2010
▫ Chief Executive Officer, Trillion Pharmaceuticals, Inc., Winston-Salem, North Carolina, 2008-2011
▫ Graduate Faculty Advisor, Western Carolina University, Cullowhee, North Carolina, 2009-2011
▫ Member, Program for Complementary and Integrative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 2009-present
EDITORIAL POSITIONS, REVIEW PANELS AND STUDY SECTIONS:
▫ Regional Editor, Current Medicinal Chemistry, 2000-present
▫ Regional Editor, Mini-Reviews in Medicinal Chemistry, 2000-2008
▫ Editorial Advisor, Current Pharmaceutical Design, 2001-present
▫ Guest Editor, Current Topics in Medicinal Chemistry, 2003 (Spring)
▫ Editorial Board Member, Journal of Chinese Pharmaceutical Sciences, 2006-present
▫ Study Section Member, "Exploiting Stress Response Pathways for Strategies to Improve Radiation Therapy" NIH 2PO1CA104457-06, 2008-2010
▫ ad hoc reviewer for: Journal of the American Chemical Society, Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry Letters, Journal of Organic Chemistry, European Journal of Medicinal Chemistry, Biophysical Journal, Journal of Natural Products
HONORS AND AWARDS:
▫ ORS Fellowship Awards Scheme, University of Bath, 1995-1998
▫ Ede and Ravenscroft Award for Exceptional Postgraduate Student Research (England), 1996
▫ Lifetime listing in Manchester Who’s Who, 2004
▫ Listing in the Empire Who’s Who Executive and Professional Registry, 2004
▫ Business Journal, Top Patent Holder, 2007
TEACHING COMPETENCIES:
▫ Graduate level: Physical Biochemistry & Biophysics (Team-taught at WFU Health Sciences, BCIM-614), Computational Chemistry, Protein Structure and Function (Team-taught at WFU Health Sciences, BCIM-708), Computational Biology, Molecular Pharmacology, Drug Discovery, Design and Development (Team-taught at WFU Health Sciences, BCIM-628)
▫ Interdisciplinary topics: Neuropharmacology and Cognition, Pharmacology, Physics and the Problem of
Consciousness, Bioinformatics, Drug Design & Development, Complex Systems and Emergent Behavior, Frontiers in the Life-Sciences: from the Human Genome to Personalized Medicine, From Shamanism to Systems Biology: The Future of Human Healthcare
▫ Advanced Topics: Classical and ab initio Molecular Dynamics, Computational Chemistry, Biophysics of Neuronal Receptors & Ion Channels, Protein Folding, Pattern Recognition & Statistical Methods in Drug Design
RESEARCH ADVISEMENT:
▫ Undergraduate Internship Advisor to: Aaron Clauset (Haverford College), 2002-2003; Vishali Mogallapu (UNC Charlotte), Summer 2004
▫ Graduate Internship Advisor to: George Jiang (WFU, Physiology and Pharmacology) 2000; George Yhorling (WFU, Physiology and Pharmacology) 2000; Ersin Bayram (WFU, Biomedical Engineering), 2003; Joshua Ayres (University of Kentucky, Pharmacy) 2003; Ryan Huff (WFU,Computer Science), 2005; Sri Kompella (WSSU, Computer Science), 2004-present
▫ Graduate (co)-Advisor to: Rebecca Harris (WFU, Computer Science) 1996-1998; Yudong Wu (Princeton University, Chemistry), 2002-2005; Aaron George (NC State, Physics), 2004-2006
▫ Postdoctoral co-advisor to: Yonas Abraham (WFU Computer Science & Physics) 2004-2007
▫ Graduate co-advisor to: Megan Arrington (WCU Chemistry & Biochemistry) 2008-2010
SELECTED PAST AND CURRENT COLLABORATORS:
▫ Robert Wykle (WFUBMC), B. Moseley Waite (WFUBMC), Leslie Poole (WFUBMC), Jacqueline Fetrow (WFU), Peter Crooks (University of Kentucky), Roberto Car (Princeton University), Stuart Kauffman (Santa Fe Institute, Institute for Informatics and Bio-complexity), Beatrice Bruteau (noted scholar Religious Studies and the History of Science; served as scientific editor of: God's Ecstasy: The Creation of a Self-Creating World, ISBN: 0-82451-6834)
SELECTED GRANTS {total awards to date: $5.9M }:
▫ RJR Nabisco Basic Research Award (PI), "Molecular modeling of nicotinic acetylcholine receptor agonists" 3/92- 9/93. $54K
▫ North Carolina Supercomputing Center Research Award (co-PI), "Molecular dynamics refinement of the alkyl hydroperoxide reductase flavoprotein: a topology fingerprint case study" 1/94-1/95 HPC time
▫ Targacept, Inc. Platform Technology Development Award (PI), 10/00-10/02, $2.16M
▫ SBIR Phase I Grant (PI), National Science Foundation, “Supervised self-organizing maps in QSAR” 6/02-1/03. Grant number: DMI-0319787, $100K
▫ ATP Grant (PI), National Institute of Standards and Technology, “A new software tool for improving drug discovery and development” 10/03-10/06. Grant number: 70NANB3H3065, $2M
▫ STTR Phase I Grant (PI), National Institutes of Health, “Fuzzy self-organizing maps in QSAR” 10/04-10/05. Grant number: GM070291-01 A1, $130K
▫ CFG Grant (co-PI), North Carolina Biotechnology Center, “Systematic development of quantum computational software” 12/06-122/07. $77K
▫ BRG Grant (PI), North Carolina Biotechnology Center, “Native Western NC botanicals as treatments for cancer” 8/07-8/08. $75K
▫ Program Initiative Grant (PI), North Carolina Biotechnology Center, “Development of particle-beam mass spectrometry for natural products research” 9/07-9/08. $60K
▫ Presidential Initiative Award (co-PI), North Carolina Biotechnology Center, “Development of a germplasm collection at Bent Creek Institute” 10/07-9/09. $100K
▫ BRG Grant (co-PI), North Carolina Biotechnology Center, “fatty acid synthase inhibitors for cancer therapy” 8/08-8/09. $75K
▫ Laboratory-Clinical Translational Award: Stage I (co-PI), DOD congressionally directed medical research program, “inhibitors of fatty acid synthase for prostate cancer” 3/09-3/12. $0.9M
AREAS OF EXPERIENCE AND RESEARCH INTEREST:
▫ Computational Biology and Chemistry: Drug design and QSAR studies; bioinformatics; complexity; Systems Biology; protein folding; molecular dynamics; energy minimization; applications of genetic algorithms, neural networks and machine learning; quantum chemical and semi-empirical methods; quantum molecular dynamics; molecular recognition; and force-field development.
▫ Organic Synthesis: Drug discovery and natural product synthesis; combinatorial chemistry & diversity-oriented synthesis; natural products; synthesis of bio-active lipid mediators; protective-group and heterocyclic compound synthesis methods; peptide and solid-phase synthesis; NMR spectrometry and techniques related to synthesis.
▫ Biophysical Methods: High-throughput screening; lab-on-a-chip; Electrophysiological techniques; lipid biophysics; NMR; EPR.
▫ Program & Capacity Development in Translational Science and Integrative Medicine
PATENTS, PATENT APPLICATIONS and PCTs:
1. Pharmaceutical Compositions and Methods for Use, G.M. Dull, C.H. Miller, J. Wagner, W.S. Caldwell, J.D. Schmitt, B.S. Bhatti and S.H. Hadamani, Submitted US Patent office 8/98 application number: 98/627-315
2. Pharmaceutical Compositions and Methods for Use, J.D. Schmitt, P. Crooks and G.M. Dull, Submitted US Patent office 12/98 application number: 98/628-023
3. Pharmaceutical Compositions and Methods for Use, Dull, G.M., Miller, C., Caldwell, W.S., Lynm, D., Bhatti, B.S., Schmitt, J.D. and Byrd, G. Submitted US Patent office 12/98 application number: 99/327,149
4. Pharmaceutical Compositions and Methods for Use, Dull, G.M., Miller, C., Caldwell, W.S., Lynm, D., Bhatti, B.S., Schmitt, J.D. and Byrd, G. Submitted US Patent office 12/98 application number: 09/327,141
5. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, preparation, pharmaceutical compositions containing them, and their use as modulators of nicotinic cholinergic receptors. Schmitt, Jeffrey Daniel; Dull, Gary Maurice; Bhatti, Balwinder Singh. PCT Int. Appl. (2001), 54 pp. WO 0132264
6. Preparation of phenylalkenylamines as nicotinic acetylcholine agonists. Dull, Gary Maurice; Wagner, Jared Miller; Caldwell, William Scott; Miller, Craig Harrison; Schmitt, Jeffrey Daniel; Bhatti, Balwinder Singh; Hadimani, Srishailkumar Basawannappa. PCT Int. Appl. (2001), 74 pp. WO 0117943
7. Preparation of aryl substituted olefinic amines as nicotinic cholinergic receptor agonists. Dull, Maurice Dull; Miller, Craig Harrison; Caldwell, William Scott; Lynm, Dwo; Bhatti, Balwinder Singh; Schmitt, Jeffrey Daniel; Byrd, Gary Dwight; Hadimani, Srishailkumar Basawannappa. PCT Int. Appl. (2000), 92 pp. WO 0075110
8. Preparation of pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors.Schmitt, Jeffrey Daniel; Crooks, Peter Anthony; Dull, Gary Maurice. PCT Int. Appl. (2000), 56 pp. WO 0034276
9. Preparation of 3-aminophenylalkenamines as nicotinic acetylcholine receptor agonists. Dull, Gary Maurice; Wagner, Jared Miller; Caldwell, William Scott; Miller, Craig Harrison; Schmitt, Jeffrey Daniel; Bhatti, Balwinder Singh; Hadimani, Srishailkumar Basawannappa PCT Int. Appl. (2000), 60 pp. WO 0023418
10. Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands. Miller, Craig Harrison; Dull, Gary Maurice; Miao, Lan; Lynm, Dwo; Schmitt, Jeffrey Daniel; Clark, Thomas Jeffrey. PCT Int. Appl. (2001), 54 pp.
11. Preparation of pyridyl olefinic and acetylenic cycloalkylamines as prodrug modulators of nicotinic cholinergic receptors and agents for central nervous system disorders. Dull, Gary Maurice; Schmitt, Jeffrey Daniel; Bhatti, Balwinder Singh; Miller, Craig Harrison. U.S. Pat. Appl. Publ. (2002), 29 pp., Cont.-in-part of U.S. Ser. No. 431,700
12. Preparation of N-aryl diazabicyclic compounds for treatment of central nervous system disorders. Miller, Craig Harrison; Dull, Gary Maurice; Miao, Lan; Lynm, Dwo; Schmitt, Jeffrey Daniel; Clark, Thomas Jeffrey. U.S. Pat. Appl. Publ. (2002), 18 pp., Cont.-in-part of U.S. Ser. No. 578,768
13. Preparation of 2-pyridylmethyl(ene)-7-azabicyclo[2.2.1]heptanes as nicotinic cholinergic receptor agonists for treatment of central and autonomic nervous system disorders. Bhatti, Balwinder Singh; Clark, Thomas Jeffrey; Miller, Craig Harrison; Schmitt, Jeffrey Daniel. PCT Int. Appl. (2002), 49 pp.
14. Preparation of phenylalkenylamines as nicotinic acetylcholine agonists. Dull, Gary Maurice; Wagner, Jared Miller; Caldwell, William Scott; Miller, Craig Harrison; Schmitt, Jeffrey Daniel; Bhatti, Balwinder Singh; Hadimani, Srishailkumar Basawannappa. U.S. (2002), 24 pp., Cont.-in-part of U.S. 6,262,124
15. Pharmaceutical compositions and methods for use. Dull; Gary Maurice; Wagner; Jared Miller ; Caldwell; William Scott; Miller; Craig Harrison; Schmitt; Jeffrey Daniel; Bhatti; Balwinder Singh; Hadimani; Srishailkumar Basawannappa: U.S. 6,310,102
16. Pharmaceutical compositions and methods for use. Schmitt; Jeffrey Daniel; Crooks; Peter Anthony; Dull; Gary Maurice: U.S. 6,432,975
17. Oxopyridinyl pharmaceutical compositions and methods for use. Dull; Gary Maurice; Miller; Craig Harrison; Caldwell; William Scott; Lynm; Dwo; Bhatti; Balwinder Singh; Schmitt; Jeffrey Daniel; Byrd; Gary Dwight: U.S. 6,455,554
18. Pharmaceutical compositions and methods for use. Clark; Thomas Jeffrey; Dull; Gary Maurice; Lynm; Dwo; Miao; Lan; Miller; Craig Harrison; Schmitt; Jeffrey Daniel: U.S. 6,440,970
19. Pharmaceutical compositions and methods for use. Bhatti, Balwinder Singh; Clark, Thomas Jeffrey; Miller, Craig H.; Schmitt, Jeffrey Daniel: U.S. 6,579,878
20. Mazurov, Anatoly A.; Klucik, Jozef; Miao, Lan; Seamans, Angela S.; Phillips, Teresa Youngpeter; Schmitt, Jeffrey Daniel; Miller, Craig Harrison. Preparation of 3-substituted-2-(arylalkyl)-1-azabicycloalkanes and methods of treatment using these compounds. U.S. Pat. Appl. Publ. (2004), 38 pp., Cont.-in-part of U.S. Ser. No. 162,129.
21. Schmitt, Jeffrey Daniel; Dull, Gary Maurice; Genevois-Borella, Arielle; Capet, Marc; Cheve, Michel. Preparation of arylvinylazacycloalkanes as nicotinic acetylcholine (nAChR) ligands. U.S. Pat. Appl. Publ. (2004), A1 20040909, 19 pp.
22. Bhatti, Balwinder Singh; Miller, Craig Harrison; Schmitt, Jeffrey Daniel; N-Aryl diazaspirocyclic compounds and methods of preparation and use thereof. (2005) US 6,956,042B2.
23. Mazurov, Anatol;, Phillips, Theresa Y.; Klucik, Josef; Miao,Lan; Seamans, Angela S.; Schmitt, Jeffrey Daniel; Miller, Craig, H 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof. (2005) US 6,953,855
24. Schmitt, Jeffrey Daniel; Dull, Gary Maurice; Genevois-Borella, Arielle; Capet, Marc; Cheve, Michel. Preparation of arylvinylazacycloalkanes and use thereof. (2006), US 7,098,331
25. Dull; Gary Maurice, Schmitt; Jeffrey Daniel, Bhatti; Balwinder Singh, Miller; Craig Harrison Pharmaceutical compositions and methods for use (2005) 09/845,526
26. Dull, Gary Maurice; Schmitt, Jeffrey Daniel; Bhatti, Balwinder Singh; Miller, Craig; Pharmaceutical Compositions and Methods for Use (2006) US 7,101,896
27. Bhatti; Balwinder S. (Winston-Salem, NC), Miller; Craig Harrison (Winston-Salem, NC), Schmitt; Jeffrey Daniel (Winston-Salem, NC); N-aryl diazaspiracyclic compounds and methods of preparation and use thereof (2007) US 7,291,731
Three additional patents and PCTs either pending or in-preparation; One provisional filing in 2009.
INVITED PUBLICATIONS AND REVIEWS:
1. Schmitt, J.D.: Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem. 7, 749-800 (2000).
2. Schmitt, J.D. and Bencherif, M.: Progress in nicotinic acetylcholine receptor based therapeutics. Ann. Rep. Med. Chem. 35, 41-51 (2000).
3. Bencherif, M. and Schmitt, J.D.: Targeting Neuronal Nicotinic Receptors: a path to New Therapies. Curr. Drug Targets- CNS & Neurological Disorders 1, 319-327 (2002).
4. Schmitt, J.D. Preface. Curr. Topic. Med. Chem. (Sharjah, United Arab Emirates) 4:6, (2004)
5. Bayram, E.; Santago, P.; Harris, R.; Xiao, Y.-D.; Clauset, A.J.; Schmitt, J.D. Genetic Algorithms and Self-Organizing Maps: a Powerful Combination for modeling Complex QSAR and QSPR Problems. J. Comp. Aided Mol. Des. 18(3) 483-493 (2004).
REFEREED PUBLICATIONS:
A. Articles
1 . Wykle, R. L., Miller, C. H., Lewis, J. C., Schmitt, J. D., Smith, J. A., Surles, J. R., Piantadosi, C., and O'Flaherty, J. T. : Stereospecific activity of 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine and comparison of analogs in the degranulation of platelets and neutrophils. Biochem. Biophys. Res. Commun. 100:1651-1658 (1981).
2. McNamara, M. J. C., Schmitt, J. D., Wykle, R. L., and Daniel, L. W.: 1-Hexadecyl-2-acetyl-sn-glycerol stimulates differentiation of HL-60 human promyelocytic leukemia cells to macrophage-like cells. Biochem. Biophys. Res. Commun. 122:824-830 (1984).
3. O'Flaherty, J. T., Schmitt , J. D., McCall, C. E., and Wykle, R. L.: Diacylglycerols enhance human neutrophil degranulation responses: relevancy to a multiple mediator hypothesis of cell function. Biochem. Biophys. Res. Commun. 123:64-70 (1984).
4 . McCall, C. E., Schmitt, J.D., Cousart, S., O'Flaherty, J.T., Bass, D., and Wykle, R.L.: Stimulation of hexose transport by human polymorphonuclear leukocytes: a possible role for protein kinase C. Biochem. Biophys. Res. Commun. 126:450-456 (1985).
5. O'Flaherty, J. T. , Schmitt, J. D. , and Wykle, R. L. : Interactions of arachidonate metabolism and protein kinase C in mediating neutrophil function. Biochem. Biophys. Res. Commun. 127:916-923 (1985).
6. O'Flaherty, J. T., Schmitt, J. D., Wykle, R. L., Redman, J. F., Jr., and McCall, C. E.: Diacylglycerols and mezerein activate neutrophils by a phorbol myristate acetate-like mechanism. J. Cell. Physiol. 125:192-199 (1985).
7. McCall, C. E., McPhail, L. C., Salzer, W. L., Schmitt, J. D., Nasrallah, V., Kim, J. , Wykle, R. L., O'Flaherty, J. T., and Bass, D. A.: Diacylglycerol activates protein kinase C and modulates oxidative metabolism in human neutrophils. Trans. Assoc. Am. Physicians 98:253-268 (1985).
8. O'Flaherty, J. T., Redman, J. F., Jr. , Schmitt, J. D., Ellis, J. M., Surles, J. R., Marx, M.H., Piantadosi, C., and Wykle, R. L. : 1-0-Alkyl-2-N-methylcarbamyl-glycerophosphocholine: a biologically potent, non-metabolizable analog of platelet-activating factor. Biochem. Biophys. Res. Commun. 147:18-24 (1987).
9. Chabot, M. C., Schmitt, J. D., Bullock, B. C., and Wykle , R. L.: Reacylation of platelet activating factor with eicosapentaenoic acid in fish-oil-enriched monkey neutrophils. Biochim. Biophys. Acta 922: 214-220 (1987).
10. Wilcox, R. W., Wykle, R. L., Schmitt, J. D., and Daniel, L. W.: The degradation of platelet activating factor and related lipids: susceptibility to phospholipases C and D. Lipids 22:800-807 (1987).
11. Surles, J. R. , Marx, M. H. , Piantadosi, C. , Schmitt, J. D. , and Wykle, R. L.: Synthesis and evidence for the stability of a glycerophosphochloridate: rac-1-0-hexadecyl-2-0- (methylcarbamyl) -sn-glycero-3- phosphorochloridocholine. J. Org. Chem. 53:899-901 (1988).
12. Bass, D. A., McPhail, L. C., Schmitt, J. D., Morris-Natschke, S., McCall, C. E. , and Wykle, R. L.: Selective priming of rate and duration of the respiratory burst of neutrophils by 1,2-diacyl and 1-0-alkyl-2-acyl diglycerides: possible relation to effects on protein kinase C. J. Biol. Chem. 263:19610-19617 (1988).
13. Daniel, L. W., Small, G. W., Schmitt, J. D., Marasco, C. J., Ishaq, K., and Piantadosi, C.: Alkyl-linked diglycerides inhibit protein kinase C activation by diacylglycerols. Biochem. Biophys. Res. Commun. 151:291-297 (1988).
14. Venable, M. E., Nieto, M. L., Schmitt, J. D., and Wykle, R. L.: Conversion of 1-0-['H]alkyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine to lyso platelet-activating factor by the CoA-independent transacylase in membrane fractions of human neutrophils. J. Biol. Chem. 266:18691-18698 (1991).
15. Parks, J. S. , Thuren, T. Y. , and Schmitt, J. D.: Inhibition of lecithin:cholesterol acyltransferase activity by synthetic phosphatidylcholine species containing eicosapentaenoic or docosahexaenoic acid in the sn-2 position. J. Lipid Res. 33:879-887 (1992).
16. Sozzani, S., Agwu, D. E., McCall, C. E., O'Flaherty, J. T., Schmitt, J. D. , Kent, J. D. , and McPhail, L. C.: Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. J. Biol. Chem. 267:20481-20488 (1992).
17. Schmitt, J. D., Nixon, A. D., Emilsson, A., Daniel, L. W., and Wykle, R. L.: A facile synthesis of 1-0-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet activating factor). Chem. Phys. Lipids 62:263-268 (1992).
18. Wilcox, R. W. , Thuren, T. , Sisson, P. , Schmitt, J. D. , Kennedy, M. , and Waite, M.: Regulation of rat hepatic lipase by composition of monomolecular films of lipid. Biochemistry 32:5752-5758 (1993).
19. Schmitt, J., Lippiello, P. M. and Caldwell, W. S.: R. J. Reynolds develops predictive models for nAchR activity. MC2 Quarterly 2, 12 (1995).
20. Amidon, B., Schmitt, J. D., Thuren, T., King, L., and Waite, M.: The biosynthetic conversion of phosphatidylglycerol to sn-l:sn-l'-bis(monoacylglycero)phosphate in a macrophage-like cell line. Biochemistry 34: 5554-5560 (1995).
22. Schmitt, J. D., Amidon, B., Wykle, R. L., and Waite, M.: Stereospecific labeling of the glycerol moiety: synthesis of 1,2-dioleoyl-sn-3-[3H]glycero-3-phosphono-rac-glycerol. Chem. Phys. Lipids 77:131-137 (1995).
23. Schmitt, J.D., Sansom, M.S.P., Kerr, I.D., Lunt, G.G, and Eisenthal R.: Ferrocenoyl derivatives of alamethicin: redox-active ion channels. Biochemistry 36:1112-1115 (1997).
24. Bencherif, M, Schmitt, J.D., Crooks, P., Lovette, M.E., Fowler, K., Reeves, L., Caldwell, W.S., and Lippiello, P.M.: The heterocyclic substituted pyridine derivative 2-azabicyclo(2,2,1)hept-5-ene [RJR-2429]: a selective agonist at nicotinic acetylcholine receptors. J. Pharm. Exp. Ther. 284:886-894 (1998).
25. Schmitt, J.D., Sharples, C.G.V., and Caldwell, W.S.: Molecular recognition in nicotinic acetylcholine receptors: the importance of pi-cation interactions. J. Med. Chem. 16:3066-3074 (1999).
26. Poole, Leslie B.; Godzik, Adam; Nayeem, Akbar; Schmitt, Jeffrey D. AhpF Can Be Dissected into Two Functional Units: Tandem Repeats of Two Thioredoxin-like Folds in the N-Terminus Mediate Electron Transfer from the Thioredoxin Reductase-like C-Terminus to AhpC. Biochemistry 39(22), 6602-6615 (2000).
27. Jiang, G.C.-T., Yohrling, G.J., Schmitt, J.D., Vrana, K.E.: Identification of substrate orienting and phosphorylation sites within tryptophan hydroxylase using homology-based molecular modeling. J. Mol. Biol. 302: 1005-1017 (2000).
28. Klucik, J.; Xiao, Y.-D.; Hammond, P.S.; Harris, R.; Schmitt, J.D. Targacept Active Conformation Search: A New Method for Predicting the Conformation of a Ligand Bound to Its Protein Target. J. Med. Chem. 47(27), 6831-6839 (2004).
29. Bayram, E.; Santago, P; Harris, R.; Xiao, Y.-D.; Clauset, A.J.; Schmitt, J.D. Genetic Algorithms and Self-Organizing Maps: a Power Combination for Modeling Complex QSAR and QSPR Problems. J. Comp. Aided Mol. Design. 18, 483-493 (2004).
30. Wu, Y.-D.; Schmitt, J.D.; Car, R. Mapping potential energy surfaces. J. Chem. Phys. 121(3), 1193-1200 (2004).
31. Mazurov, A.; Klucik, J.; Miao, L.; Phillips, T.Y.; Seamans, A.; Schmitt, J.D.; Hauser, T.A., Johnson, R.T.; Miller, C.H. 2-(Arylmethyl)-3-Substituted Quinuclidines as Selective α7 Nicotinic Receptor Ligands. Bioorg. Med. Chem. Lett. 15(8), 2073-2077 (2005).
32. Hammond, P.S.; Wu, Y.-D.; Harris, R.; Minehardt, T.; Car, R.; Schmitt, J.D. Protonation-Induced Stereoisomerism in Nicotine: Conformational Studies Using Classical and ab initio Molecular Dynamics. J. Comp. Aided Mol. Des. 19(1), 1-15 (2005).
33. Xiao, Y.-D.; Clauset, A.; Harris, R.; Bayram, E.; Santago, P.; Schmitt, J.D. Supervised SOMs in Drug Discovery I: Robust Behavior with Overdetermined Datasets. J. Chem. Inf. Mod. 2005; 46(1); 137-144.
34. Xiao, Y.-D.; Harris, R.; Bayram, E.; Santago, P.; Schmitt, J.D. Supervised SOMs in Drug Discovery II: Improvements in Feature Selection and Model Validation. J. Chem. Inf. Mod. 2006; 45(6); 1749-1758.
35. Ayres, J.; Clauset, A.; Schmitt, J.D.; Dwoskin, L.P.; Crooks, P.A. A Molecular Modeling Study of Mono- and
Bis- Quarternary Ammonium Salts at the a4b2 Nicotinic Acetylcholine Receptor Subtype Using Nonlinear
Techniques. Proc. Am. Assoc. Pharm. Sci. 2005; 7(3), E678-E685
36. George, A.; Mogallapu, V.; Harris, R.; Abraham, Y.; Car, R.; Schmitt, J.D. Orbital Energetics and Molecular
Recognition. J. Am. Chem. Soc. 2006; 128(14), 4514-4515
37. Zheng, F.; Bayram, E.; Schmitt, J.D.; Dwoskin, L.; Crooks, P.A. QSAR Modeling of mono- and bis-Quaternary
Ammonium Salts that Act as Antagonists at Neuronal Nicotinic Acetylcholine Receptors Mediating
Dopamine Release. Bioorg. Med. Chem. 2006; 14(9), 3017-3037
38. George, A.; Abraham, Y.; Harris, R.; Car, R.; Schmitt, J.D. QSAR and QSPR Analysis Using Dynamic
Eiganvalue Descriptors. Manuscript in preparation
39. Kelly, R.M.; Clement, J.A.; Kelly, J.; Schmitt, J.D. Cytotoxic components of Arnoglossum triplicifolium.
Manuscript in preparation
40. Clement, J.A.; Kelly, R.M.; Schmitt, J.D. Anti-cancer components of Aralia racemosa. Manuscript in
preparation
41. Arrington, M.; Schmitt, J.D.; Summers J. Plant flavinoid inhibition of superoxide dismutase: a new path to
therapeutics for cancer and infectious disease. Manuscript in preparation
42. Schmitt, J.D.; Pemble, C.; Kridel, S.; Lowther, T. Chainlength specificity and acyl carrier protein interaction in
the catalytic cycle of fatty acid synthase thioesterase domain. Manuscript in preparation
B. Abstracts & Proceedings
1. Schmitt, J. D., Bencherif, M., Lippiello, P. M., Lovette, M. E., Arrington, S., Reeves, L. K. and Caldwell, W. S.: Quantitative structure-activity relationship studies on nicotine and ABT-418 congeners: Implications for distinct modes of high affinity binding in rat brain. Abst.. Soc. Neurosci. 21: 72 (1995).
2. Caldwell, W. S., Schmitt, J. D., Bencherif, M. and Lippiello, P. M.: A combinatorial model of the nicotinic acetylcholine receptor pharmacophore. Abst . Soc. Neurosci. 21: 72 (1995).
3. Schmitt, J., Bencherif, M., Lippiello, P. M., Lovette, M. E. and Caldwell, W. S.: Quantitative structure-activity relationship studies on nicotine analogs: structural determinants of high affinity binding in rat brain. Abst. Am. Assoc. Pharm. Sci. MNPC: 5008 (1995).
4. Bencherif, M., Crooks, P.A., Bhatti, B.S., Deo, N.M., Caldwell, W.S., Schmitt, J.D., Lovette, M.E., Fowler, K., Reeves, L., and Lippiello, P.M.: Azabicyclic nicotine analogs: potent agonists at nicotinic acetylcholine receptors. Abst. Am. Assoc. Pharm. Sci. MNPC: 5008 (1995).
5. Schmitt, J. D., Bencherif, M., Lippiello, P. M., Lovette, M. E., Arrington, S., Reeves, L. K. and Caldwell, W. S.: The nicotinic acetylcholine receptor: structure-activity and pharmacophore modeling. Poster presentation, Biannual Molecular Simulations User Group Meeting, Queens College, Cambridge University, Cambridge, United Kingdom (1995).
6. Schmitt, J. D., Bencherif, M., Lippiello, P. M., Lovette, M. E., Arrington, S., Reeves, L. K. and Caldwell, W. S.: Insights into high-affinity binding to nicotinic acetylcholine receptors. Poster presentation, Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy, Nice, France, April 10-14 (1996).
7. Caldwell, W.S., Bencherif, M., Bhatti, B. S., Deo, N. M., Dobson, G. P., Dull, G. M., Lippiello, P.M., Lovette, M. E., Miller, C. H., Ravard, A., Schmitt, J. D. and Crooks, P. A.: Synthesis and structure-activity relationships of analogs of rjr-2403, a CNS-selective nicotinic agonist. Poster presentation, Fifth International Nice/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 14-19 (1998).
8. Schmitt, J.D., Sharples, C.G.V., and Caldwell, W.S.: Aromatic-cation interactions in nicotinic acetylcholine receptor ligand binding. Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-153. Publisher: American Chemical Society, Washington, D. C.
9. Bhatti, B.S., Schmitt, J.D., Deo, N.D., Bencherif, M., Crooks, P.A., and Caldwell, W.S.: 2-(3-Pyridyl)-1-azatricyclo[3.3.1.1<3,7>]decane), RJR-2531, a potent antagonist at the nicotinic acetylcholine receptor. Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-154. Publisher: American Chemical Society, Washington, D. C.
10. Crooks, P.A., Bhatti, B. S., Deo, N. M., Schmitt, J.D., Lippiello, P.M., and Caldwell, W.S.: Synthesis and structure-activity relationships of analogs of 2-(3-pyridyl)-1-azabicyclo[2.2.2]octane, RJR-2429, a selective ligand at nicotinic acetylcholine receptors. Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-144. Publisher: American Chemical Society, Washington, D. C.
11. Dull, G.M., Bencherif, M., Bhatti, B. S., Deo, N. M., Dobson, G. P., Dull, G. M., Lippiello, P.M., Lovette, M. E., Miller, C. H., Ravard, A., Schmitt, J. D., Crooks, P. A. and Caldwell, W.S.: Synthesis and structure-activity relationships of analogs of rjr-2403, a CNS-selective nicotinic agonist. Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-143. Publisher: American Chemical Society, Washington, D. C.
12. Schmitt, J.D., Sharples, C.G.V., and Caldwell, W.S.: Molecular Recognition in the Nicotinic Acetylcholine Receptor: Probing the Role of Aromatic-cation interactions. Abst. Neurosci. Soc. (1998).
13. Bhatti, B. S., Schmitt, J.D., Benchreif, M., and Caldwell, W.S.: Synthesis and structure-activity relationships of analogs of 2-(3-pyridyl)-1-azabicyclo[2.2.2]octane, RJR-2429, a selective ligand at nicotinic acetylcholine receptors. Book of Abstracts, 219th ACS National Meeting, San Francisco, March 24-27 (2000), MEDI-144. Publisher: American Chemical Society, Washington, D. C.
14. Bhatti, Balwinder; Tahiri, Prashida; Schmitt, Jeff; Caldwell, William S.; Bencherf, Merouane. Enantiomeric synthesis of pyridyl quinuclidines. Book of Abstracts, 224th ACS National Meeting, Boston, MA, March 26-30 (2000).
15. P.S. Hammond, R. Car*, R. Harris, J. D. Schmitt. Protonation -Induced Stereoisomerism In Tertiary Amines; Application Of QM-Based Molecular Dynamics Methods. Book of Abstracts, 224th ACS National Meeting, San Francisco, CA, March 26-30 (2002).
16. A. J. Clauset, P. S. Hammond, R. Harris, J. D. Schmitt; TACS (Targacept Active Conformation Search) A New Method For Predicting The Conformation Of A Ligand Bound To Its Protein Target. Book of Abstracts, 224th ACS National Meeting, Boston, MA, March 26-30 (2002).
17. A. J. Clauset, R. Harris, J. D. Schmitt. Novel Use Of Self-Organizing Feature Maps In QSAR Studies. Book of Abstracts, 224th ACS National Meeting, Boston, MA, March 26-30 (2002).
18. Xiao, Y.-D.; Klucik, J.; Harris, R.; Schmitt, J.D.. Principal curves analysis and self-organizing maps in QSAR: A comparative study. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003).
19. Wu, Y.-D.; Hammond, P.S.; Minehardt, T.J.; Schmitt, J.D.; Car, R. Application of a coarse-grained dynamical method to explore the conformational space of small molecules. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003).
20. Schmitt, J.D.; Harris, R.; Bayram, E.; Xiao, Y.-D.; Santago, P., II. Coupling feature reduction with self-organizing maps for drug discovery. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004 (2004), COMP-252.
21. Xiao, Y.-D.; Bayram, E.; Harris, R.; Santago, P., II; Schmitt, J.D. Use of simulated annealing with supervised self-organizing maps for QSAR and QSPR studies. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004 (2004), COMP-237.
22. Bayram, E.; Santago, P.; Harris, R.; Xiao, Y.-D.; Clauset, A. J.; Schmitt, J. D. Genetic algorithms and self-organizing maps: A powerful combination for modeling complex QSAR and QSPR problems. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004 (2004), COMP-229.
23. Mazurov, A.; Klucik, J.; Miao, L.; Phillips, T.Y.; Seamans, A.; Schmitt, J.D.; Miller, C. Selective 7 nicotinic receptor ligands. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004 (2004), MEDI-083.
24. Schmitt, J.D.; Bhatti, B. S.; Breining, S.R.; Hammond, P.S.; Harris, R.; Hawkins, G.D.; Klucik, J.; Miao, L.; Miller, C.H.; Xiao, Y.-D.; Phillips, T.Y.; Seamans, A.; Caldwell, W.S. Adventures in the rational design of nicotinic acetylcholine receptor therapeutics. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004 (2004), MEDI-022.
25. Shelley, M.; Hammond, P.S.; Minehardt, T.; Schmitt, J.D. Docking studies involving a homology model of an alpha-7 human neuronal nicotinic receptor. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005 (2005), MEDI-093.
26. Hammond, P.S.; Shelley, M.Y.; Minehardt, T.; Xiao, Y.-D.; Klucik, J.; Schmitt, J.D. Human alpha-7 neuronal nicotinic receptor docking studies as an alignment method for Comparative Molecular Field Analysis (CoMFA). Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005 (2005), MEDI-095.
27. Abraham, Y.; Harris, R.; Hammond, P. S.; George, A.; Schmitt, J.D. Free energy versus potential energy landscapes of drug-like molecules, Abstracts of Papers, APS National Meeting, Baltimore MD, March 13, 2006 (2006)
28. George, A.; Abraham, Y.; Harris, R.; Sbraccia, C.; Car, R.; Schmitt, J.D. DYNEVA: Electronic eigenvalues descriptors derived from quantum molecular dynamics, Abstracts of Papers, Electronic Structure 2005 Meeting, Ithaca NY, June 23 - 26, 2005
29. George, A.; Abraham, Y.; Harris, R.; Sbraccia, C.; Car, R.; Schmitt, J.D. Orbital energetics and molecular recognition. Abstracts of Papers, APS National Meeting, Baltimore MD, March 13, 2006
30. Abraham, Y.;George, A.; Harris, R.; Sbraccia, C.; Car, R.; Schmitt, J.D. Free-energy versus potential energy landscapes of drug-like molecules. Abstracts of Papers, ACS National Meeting, San Francisco CA, September 14, 2006
31. Pauca, V; Abraham,Y.; Torgersen, T.; Harris, R.; J.D. Schmitt, J.: Automating the Development of Quantum Computational Software, Proceedings of the 2007 ACM Southeast Conference, 2007
32. Willis, T.J.; Clement, J.A.; Kelly, R.M.; McCoy, J.A.; Schmitt, J.D. Isolation of Cytotoxic Compounds from Indigenous Plants of Western North Carolina. Southeastern Regional Meeting of the American Chemical Society, Nashville, TN, November 15, 2008
33. Clement, J.A.; Willis, T.J.; Kelly, R.M.; Schmitt, J.D. Antitumor Activity of Aralia racemosa. International Conference on the Science of Botanicals. Oxford, MS, April 6-9, 2009. Planta Medica 75, 2009
34. Kelly, R.M.; Clement, J.A.; Schmitt, J.D. Antitumor Activity of Arnoglossum atriplicifolium. International Conference on the Science of Botanicals. Oxford, MS, April 6-9, 2009. Planta Medica 75, 2009
INVITED PRESENTATIONS (selected from 200):
1. The Biophysics of Channel Forming Peptides: Studies Using Redox-Active Derivatives of Alamethicin. presentation, Department of Biochemistry, Wake Forest University Medical Center. October 23, 1996.
2. The Neuronal Structure of the Brain. Invited presentation, The Bath Royal Literary and Scientific Institution. September 8, 1997.
3. The Biophysics of Channel Forming Peptides: Redox-Active Peptides. Invited presentation, Department of Physiology and Biophysics, Mayo Clinic. June 19, 1998.
5. The Biophysics of Channel Forming Peptides: Redox-Active Peptides. Invited presentation. Department of Biochemistry, Wake Forest University Medical Center. July 8, 1998.
6. Artificial Neural Networks and Brain Function. Invited Presentation, N. Carolina Governor’s School. July 17, 1999.
7. 1999 Alumni Symposium Lecture: Science and the Nature of Consciousness. Invited Presentation given with Dr. B. Bruteau, N. Carolina Governor’s School. July 24, 1999.
8. Non-linear Statistical Methods in QSAR: Nicotinic Acetylcholine Receptors and Beyond. Invited presentation, University of Kentucky School of Pharmacy. September 7, 2001.
9. Beyond Methyl, Ethyl, Butyl, Futile: New frontiers In Drug Design at Targacept. Invited presentation, Symposium of Biochemistry and Biotechnology, Wake Forest University School of Medicine. June 7, 2002.
10. Rational Design of Nicotinic Acetylcholine Receptor Therapeutics. Invited presentation, 14th Annual Camerino-Noordwijkerhout Symposium: Ongoing Progress in Receptor Chemistry: September 7, 2003.
11. Adventures in the Rational Design of Nicotinic Acetylcholine Receptor Therapeutics. 228th ACS National Meeting, Philadelphia, PA, August 24, 2005.
12. Structural Models and the Design of Nicotinic Acetylcholine Receptor Therapeutics. 228th AAPS National Meeting, Philadelphia, PA, October 15, 2005.
13. Science at the Interface. Bringing Biotechnology to North Carolina Conference, Asheville, NC, February 27, 2006.
14. Emerging IT Companies Panel. Innovation Leadership Summit. North Carolina Technology Association Summit 2006, Charlotte NC, May 23, 2006.
15. Frontiers in Predictive ADMET Symposium. Organizer and Moderator. The Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 1, 2006.
16. An Introduction to the International Center for Natural Biotechnology and Integrative Medicine. The 2nd Annual Life Science Economic Development Summit, Research Triangle Park, NC December 7, 2006.
17. An Introduction to the International Center for Natural Biotechnology and Integrative Medicine. The Annual Meeting of the North Carolina Natural Products Association, Boone, NC December 12, 2006.
18. The madness of King George and the Tears of the Norway Rat: Adventures in the Rational Design of Nicotinic Acetylcholine Receptor Therapeutics. Chemistry Department, Appalachian State University, Boone, NC, August 21, 2007.
19. Rational Design Approaches in Developing Treatments for Nervous System Disorders. Graylyn Conference on Women’s Cognitive Health, Wake Forest University, Winston-Salem NC, October 26, 2007.
20. The madness of King George and the Tears of the Norway Rat: Adventures in the Rational Design of Nicotinic Acetylcholine Receptor Therapeutics. Chemistry Department, Davidson College, Davidson, NC, February 8, 2008.
21. Systems Biology and the Future of Medicine. Conference on Neutragenomics. Wake Forest University Health Sciences, Winston-Salem, NC, May 7, 2009.